Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149559 · ClinicalTrials.gov registry record · Phase 2
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
A Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 13
- Study locations
NCT06149559 is a Phase 2 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 12 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 2 states.
The verdict
NCT06149559, a Phase 2 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
Conditions Studied
Interventions
- DRUG rozanolixizumab
Study Locations (13)
Other
- Mg0006 40290 - Bologna
- Mg0006 40144 - Milan
- Mg0006 40733 - Naples
- Mg0006 20340 - Fuchu-shi
- Mg0006 20339 - Ōbu
- Mg0006 20343 - Sagamihara
- Mg0006 40155 - Warsaw
- Mg0006 40734 - Warsaw
- Mg0006 20081 - Taipei
- Mg0006 20095 - Taipei
- Mg0006 40841 - Altindağ/ankara
- Mg0006 40836 - Kocaeli
Texas
- Mg0006 50574 - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2026-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06149559
The ClinicalTrials.gov registry entry for NCT06149559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which rozanolixizumab is the first listed.
NCT06149559 reports 13 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT06149559 about?
NCT06149559 is a clinical study titled "A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis". The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
What is the current status of trial NCT06149559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-06-14. Estimated completion is 2026-08-17.
What conditions does trial NCT06149559 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06149559?
The interventions under investigation include: rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT06149559?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149559 being conducted?
This trial has 13 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
RECRUITING · Phase 2
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.